Physician profile
Robert S Greenfield
NPI 1649307000
$26,978.06
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $1,214 · 2021: $3,536 · 2022: $297 · 2023: $145 · 2024: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617 · Travel and Lodging: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.66 |
| Travel and Lodging | $505.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,489.10 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $4,336.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $3,847.89 | 2019-2021 | |
| Medtronic, INC. | $929.70 | 2024 | Micra |
| Novartis Pharmaceuticals Corporation | $500.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.44 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $188.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $185.77 | 2019-2021 | |
| Esperion Therapeutics, INC. | $165.55 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $154.68 | 2019-2022 | |
| Amarin Pharma, INC. | $141.93 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.48 | 2019 | |
| Novo Nordisk INC | $130.91 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $122.20 | 2021 | |
| Pfizer INC. | $84.11 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $47.40 | 2024 | Assure Wcd |
| Otsuka America Pharmaceutical, INC. | $46.25 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $35.71 | 2021 | |
| Lundbeck LLC | $34.16 | 2019 | |
| Bardy Diagnostics, INC. | $31.21 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.48 | 2021 | |
| Merck Sharp & Dohme LLC | $22.91 | 2021 | |
| Aegerion Pharmaceuticals, INC. | $21.85 | 2019 | |
| Abbott Laboratories | $19.86 | 2023 | Amplatzer Amulet |
| Teleflex LLC | $16.58 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.35 | 2019 | |
| Gilead Sciences, INC. | $14.26 | 2019 | |
| Amryt Pharma Holdings LTD | $12.01 | 2021 | |
| Travere Therapeutics, INC. | $3.32 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greenfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.